LIFE GOAST Green Organic Agents for Sustainable Tanneries (LIFE16 ENV/IT/000416)

Content: Leather manufacturing is classified as water, energy and waste intensive by the Industrial Emissions Directive (2010/75/EU). Tannery effluents, if not properly treated, cause significant damage to soil and water bodies. Over 85% of world leather production involves the traditional chrome tanning process (TCTP). The use of chrome (Cr) in the industrial processing of animal hides poses serious environmental and health problems due to the use of hazardous chemicals, the production of solid/liquid waste and air emissions. LIFE GOAST aims at demonstrating the benefits of a new tanning technology on a semi-industrial scale; the project started on July 2017 and is an ongoing investigation, and involves the competences of three direct actors in the leather industry such as GSC Group spa as chemical supplier, Conceria Pasubio as tannery and Mediochiampo as waste-water treatment agency, in conjunction with the expertise of Università di Venezia, thus forming together a model of leather industry. The technical feasibility of LIFE GOAST implementation, as well as its social and economic impact, have been monitored and compared with the TCTP in order to demonstrate the reduced environmental impacts of the new process, while producing comparable or better quality leather. The LIFE GOAST team demonstrated that it was possible to treat collagen with the GOAST technology to give stabilised collagen to be used in the leather industry. A series of leather swatches were realised in accordance with the new protocol in order to obtain preliminary information on chemical oxygen demand COD of the effluents and technical feasibility of the process. The results were remarkable: COD values were lower than TCTP and it was possible to obtain soft and firm grain leather despite a shrinkage temperature lower than chromium process. However, these preliminary results allowed to process bigger pieces of leather (quarter, half and entire) to demonstrate that the technology was reproducible and in line with the small trials. The investigation is still ongoing and the team is fully committed to focus on the objectives of the project. Take-Away: Novel and alternative tanning systems to traditional chrome tanning

LIFE GOAST Green Organic Agents for Sustainable Tanneries (LIFE16 ENV/IT/000416)

Content: Leather manufacturing is classified as water, energy and waste intensive by the Industrial Emissions Directive (2010/75/EU). Tannery effluents, if not properly treated, cause significant damage to soil and water bodies. Over 85% of world leather production involves the traditional chrome tanning process (TCTP). The use of chrome (Cr) in the industrial processing of animal hides poses serious environmental and health problems due to the use of hazardous chemicals, the production of solid/liquid waste and air emissions. LIFE GOAST aims at demonstrating the benefits of a new tanning technology on a semi-industrial scale; the project started on July 2017 and is an ongoing investigation, and involves the competences of three direct actors in the leather industry such as GSC Group spa as chemical supplier, Conceria Pasubio as tannery and Mediochiampo as waste-water treatment agency, in conjunction with the expertise of Università di Venezia, thus forming together a model of leather industry. The technical feasibility of LIFE GOAST implementation, as well as its social and economic impact, have been monitored and compared with the TCTP in order to demonstrate the reduced environmental impacts of the new process, while producing comparable or better quality leather. The LIFE GOAST team demonstrated that it was possible to treat collagen with the GOAST technology to give stabilised collagen to be used in the leather industry. A series of leather swatches were realised in accordance with the new protocol in order to obtain preliminary information on chemical oxygen demand COD of the effluents and technical feasibility of the process. The results were remarkable: COD values were lower than TCTP and it was possible to obtain soft and firm grain leather despite a shrinkage temperature lower than chromium process. However, these preliminary results allowed to process bigger pieces of leather (quarter, half and entire) to demonstrate that the technology was reproducible and in line with the small trials. The investigation is still ongoing and the team is fully committed to focus on the objectives of the project. Take-Away: Novel and alternative tanning systems to traditional chrome tanning

The antiphospholipid syndrome and infections in a child with trisomy 21.

The relationship between infections and antiphospholipid antibodies or antiphospholipid syndrome is an intriguing question. A two and a half year old child with trisomy 21, who suffered three severe episodes of thrombosis each taking place after an infection, is described here. As high titres of IgG anticardiolipin (ACL) antibodies was registered during the second and third episodes, the antiphospholipid syndrome was suspected. IgM as well as IgG and IgA ACL antibodies have been described at different titres in a wide variety of infections, although they are not usually associated with thrombosis. In this particular case the timing of events and their association with high IgG ACL antibody titres seemed to implicate infection in the pathogenesis of the antiphospholipid syndrome. It can be hypothesized that some infections not only "trigger" antiphospholipid antibody production, but--in genetically predisposed subjects--can induce the clinical manifestations of the antiphospholipid syndrome

LIFE GOAST Green Organic Agents for Sustainable Tanneries (LIFE16 ENV/IT/000416)

Content: Leather manufacturing is classified as water, energy and waste intensive by the Industrial Emissions Directive (2010/75/EU). Tannery effluents, if not properly treated, cause significant damage to soil and water bodies. Over 85% of world leather production involves the traditional chrome tanning process (TCTP). The use of chrome (Cr) in the industrial processing of animal hides poses serious environmental and health problems due to the use of hazardous chemicals, the production of solid/liquid waste and air emissions. LIFE GOAST aims at demonstrating the benefits of a new tanning technology on a semi-industrial scale; the project started on July 2017 and is an ongoing investigation, and involves the competences of three direct actors in the leather industry such as GSC Group spa as chemical supplier, Conceria Pasubio as tannery and Mediochiampo as waste-water treatment agency, in conjunction with the expertise of Università di Venezia, thus forming together a model of leather industry. The technical feasibility of LIFE GOAST implementation, as well as its social and economic impact, have been monitored and compared with the TCTP in order to demonstrate the reduced environmental impacts of the new process, while producing comparable or better quality leather. The LIFE GOAST team demonstrated that it was possible to treat collagen with the GOAST technology to give stabilised collagen to be used in the leather industry. A series of leather swatches were realised in accordance with the new protocol in order to obtain preliminary information on chemical oxygen demand COD of the effluents and technical feasibility of the process. The results were remarkable: COD values were lower than TCTP and it was possible to obtain soft and firm grain leather despite a shrinkage temperature lower than chromium process. However, these preliminary results allowed to process bigger pieces of leather (quarter, half and entire) to demonstrate that the technology was reproducible and in line with the small trials. The investigation is still ongoing and the team is fully committed to focus on the objectives of the project. Take-Away: Novel and alternative tanning systems to traditional chrome tanning

Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: Report of four cases and review of the literature

Catastrophic Antiphospholipid Syndrome (CAPS) is a rare (1%), life-threatening variant of Antiphospholipid Syndrome (APS). It has been found that the recovery rate is best when the treatment protocol includes anticoagulants, steroids and therapeutic plasma exchange (TPE). The treatment of CAPS with TPE is not, however, well defined as procedure modalities have not yet been standardized, and the best replacement fluid for TPE is still a controversial issue. Although the most commonly used one, fresh frozen plasma (FFP), contains natural anticoagulants, it is also made up of clotting factors, complement activation products and cytokines which could worsen CAPS' "thrombotic storm". The successful management of 4 CAPS patients, including TPE sessions initiated in the 1st week from diagnosis and using albumin solution as the replacement fluid, is described here. TPE was performed daily for the first 3 days, then tapered off, and withdrawn on the basis of patient's clinical condition. One of the patients was also treated with anticoagulants, while the others received anticoagulants plus high doses of steroids in addition to TPE. Our results indicate that, when initiated promptly and albumin solution is used as the replacement fluid, TPE can be considered an effective, safe treatment for CAPS

Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.

A second-line treatment protocol including plasma exchange (PE) in addition to the standard therapies was scheduled and utilized in our hospital with the intent of improving the outcome of high risk pregnancies of women with primary antiphospholipid syndrome (APS). This paper chronologically reports and discusses the results obtained in these patients over a 15-year period. Between April 1991 and September 2006, 142 pregnancies of patients with APS were followed by us. Nine of these (6.3%), who did not respond to the conventional procedures or showed complications during the treatments were shifted to a PE protocol management. All these women had a history of previous thromboembolism associated to triple antiphospholipid antibody positivity. Nine pregnancies of 7 patients (2 women were treated twice) were thus followed using PE therapy, which has undergone modification over the years. In the cases studied the outcome of pregnancy varied according to the different PE therapy conditions. This study suggests that prophylactic PE treatment administered along with full anticoagulation and IVIG therapy could be a valuable therapeutic option in high risk pregnant APS women. Further studies in this type of patients are certainly warranted